<DOC>
	<DOCNO>NCT00140101</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy ZoMaxx drug-eluting stent patient blockage native coronary artery . The study design demonstrate non-inferiority TAXUS Express2 Paclitaxel-Eluting Stent proven superior bare metal stent recognize standard care .</brief_summary>
	<brief_title>Safety Efficacy ZoMaxx™ Drug-Eluting Stent System Coronary Arteries</brief_title>
	<detailed_description>Coronary artery disease major cause morbidity mortality United States . The American Heart Association estimate 571,000 Percutaneous Transluminal Coronary Angioplasty ( PTCA ) procedures performed 2001 United States 80 % 90 % patient also underwent stent placement . Despite effectiveness intracoronary stent maintain large luminal diameter compare angioplasty alone , 15 35 % in-stent restenosis occur within 6 9 month stent placement . While stent reduce restenosis block vascular recoil remodeling , mechanical intervention alone incapable treat biological problem neointimal hyperplasia . Various approach use treat in-stent restenosis , include balloon angioplasty , repeat stenting , rotational directional atherectomy , laser , local delivery radiation time stenting ( brachytherapy ) . However , technique add complexity interventional procedure document success prevent in-stent restenosis . Drug-eluting stent ( DES ) use antiproliferative agent deliver via polymer base stent platform show significant success reduction restenosis de novo lesion traditional bare metal stent randomize clinical trial . Local delivery pharmacological agent allow control delivery high drug concentration target tissue minimize systemic drug effect . The ZoMaxx II Trial represent first US study ZoMaxx ( TM ) Drug Eluting Coronary Stent System evaluate potential benefit local application zotarolimus drug combination phosphorylcholine ( PC ) -coated tri-metal stent . ZoMaxx™ Drug-Eluting Stent System Investigational device . Limited Federal ( U.S. ) law investigational use .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria include follow : Subject ≥ 18 year old Subject eligible percutaneous coronary intervention ( PCI ) single lesion require treatment Subject acceptable candidate CABG Clinical evidence ischemic heart disease positive functional study Documented stable angina pectoris The target lesion single de novo coronary artery lesion ≥50 &lt; 100 % stenosis visual estimate Exclusion Criteria include follow : Female childbearing potential . Female subject must medically surgically sterile diagnose postmenopausal ( i.e . one year since final menstrual cycle . Evidence acute myocardial infarction and/or CKMB &gt; 2x upper limit normal within 72 hour intend treatment Known allergy follow : aspirin , clopidogrel ( Plavix ) ticlopidine ( Ticlid ) , heparin , stainless steel , tantalum , contrast agent ( adequately premedicated ) , paclitaxel drug similar zotarolimus ( ABT578 ) ( i.e . tacrolimus , sirolimus , everolimus ) A platelet count &lt; 100,000 cells/mm3or &gt; 700,000 cells/mm3 ; WBC &lt; 3,000 cells/mm3 ; hemoglobin &lt; 10.0g/dL Acute chronic renal dysfunction ( creatinine &gt; 2.0 mg/dl &gt; 150µmol/L ) Subject previous plan brachytherapy target vessel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>drug elute stent</keyword>
	<keyword>stent</keyword>
	<keyword>angioplasty</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>total coronary occlusion</keyword>
	<keyword>coronary artery restenosis</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>vascular disease</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>coronary artery stenosis</keyword>
</DOC>